Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Erasca, Inc.
  6. Summary
    ERAS   US29479A1088

ERASCA, INC.

(ERAS)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
4.350 USD   +4.82%
07:56aMorgan Stanley Upgrades Erasca to Overweight From Equal Weight, $15 Price Target
MT
02/01Erasca to Present at the Guggenheim Oncology Conference 2023
AQ
01/10Insider Buy: Erasca
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/30/2023 01/31/2023 02/01/2023 02/02/2023 02/03/2023 Date
3.97(c) 4(c) 4(c) 4.15(c) 4.35 Last
1 344 944 1 312 709 857 706 1 201 219 1 881 730 Volume
-1.73% +0.76% 0.00% +3.75% +4.82% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -146 M - -
Net cash position 2022 311 M - -
P/E ratio 2022 -3,30x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -175 M - -
Net cash position 2023 147 M - -
P/E ratio 2023 -3,39x
Yield 2023 -
Capitalization 653 M 653 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 123
Free-Float 72,1%
More Financials
Company
Erasca, Inc is a clinical-stage precision oncology company. The Company is focused on discovering, developing and commercializing therapies for RAS/MAPK pathway-driven cancers. The Company is engaged in oncology and RAS targeting to create therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. The Company’s lead product candidates are ERAS-007 and... 
Read more
More about the company
Ratings of Erasca, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about ERASCA, INC.
07:56aMorgan Stanley Upgrades Erasca to Overweight From Equal Weight, $15 Price Target
MT
02/01Erasca to Present at the Guggenheim Oncology Conference 2023
AQ
01/10Insider Buy: Erasca
MT
01/09Erasca : Corporate Presentation January 2023
PU
01/09Erasca, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/04Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference
GL
01/04Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference
GL
2022Insider Buy: Erasca
MT
2022Erasca Doses First Patient in Phase 1b Trial of Solid Tumor Combination Therapy
MT
2022Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 a..
GL
2022Insider Buy: Erasca
MT
2022Erasca Gets FDA Clearance for ERAS-3490 Cancer Therapy Trial
MT
2022Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor..
GL
2022Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor..
AQ
2022Erasca, Inc. Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inh..
CI
More news
News in other languages on ERASCA, INC.
01/10Achat d'initiés : Erasca
2022Achat d'initiés : Erasca
2022Erasca administre la dose au premier patient de l'essai de phase 1b de la thérapie comb..
2022Achat d'initiés : Erasca
2022Erasca obtient l'autorisation de la FDA pour l'essai de la thérapie anticancéreuse ERAS..
More news
Analyst Recommendations on ERASCA, INC.
More recommendations
ETFs positioned on ERASCA, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Virtus LifeSci Biotech Clinical Trials ETF - USD1.02%4.68%United_States
ALPS Medical Breakthroughs ETF - USD0.41%2.32%United_States
Global X S&P Biotech ETF - AUD0.11%4.44%-United_States
SPDR S&P Biotech ETF - USD0.11%0.94%United_States
Invesco Nasdaq Biotechnology ETF - USD0.1%-0.46%-United_States
More ETFs positioned on ERASCA, INC.
Chart ERASCA, INC.
Duration : Period :
Erasca, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERASCA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 4,35 $
Average target price 18,60 $
Spread / Average Target 328%
EPS Revisions
Managers and Directors
Jonathan E. Lim Chairman & Chief Executive Officer
David M. Chacko Chief Business Officer
Michael D. Varney Chairman-Research & Development
Wei Lin Chief Medical Officer
Robert Shoemaker Vice President-Biology
Sector and Competitors
1st jan.Capi. (M$)
ERASCA, INC.-3.71%623
MODERNA, INC.-2.96%67 750
IQVIA HOLDINGS INC.17.45%44 698
LONZA GROUP AG20.64%44 536
ALNYLAM PHARMACEUTICALS, INC.-5.36%28 266
SEAGEN INC.8.50%25 887